WO2023131893 - SCHLEMM'S CANAL DRUG ELUTING DEVICE AND METHOD
National phase entry:
Publication Number
WO/2023/131893
Publication Date
13.07.2023
International Application No.
PCT/IB2023/050084
International Filing Date
05.01.2023
Title **
[English]
SCHLEMM'S CANAL DRUG ELUTING DEVICE AND METHOD
[French]
DISPOSITIF ET PROCÉDÉ D'ÉLUTION DE MÉDICAMENT DANS LE CANAL DE SCHLEMM
Applicants **
ALCON INC.
Inventors
TRAUTHEN, Brett A.
Priority Data
63/297,133
06.01.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1880 | |
| EPO | Filing, Examination, Granting | 8126 | |
| Japan | Filing, Examination, Granting | 1970 | |
| South Korea | Filing, Examination, Granting | 1694 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,410
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A method of delivering a pharmaceutical composition to Schlemm's canal of an eye is disclosed. The method may comprise inserting a drug delivery device in conjunction with a microstent into Schlemm's canal. The drug delivery device may comprise a bioerodable polymer and a pharmaceutical composition, and the drug delivery device may be configured to erode over time and to elute the pharmaceutical composition into aqueous humor within Schlemm's canal as it erodes.